Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers

Matteo Santoni, Alessia Cimadamore, Francesco Massari, Francesco Piva, Gaetano Aurilio, Angelo Martignetti, Marina Scarpelli, Vincenzo Di Nunno, Lidia Gatto, Nicola Battelli, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi

Research output: Contribution to journalArticle

Abstract

Background: In human populations, a certain amount of data correlate obesity/body mass index (BMI) with urothelial cancer (UC) and prostate cancer (PCa) occurrence, however this is not fully elucidated at all stages of disease. In an attempt to shed light on uncertain areas in such field, in the present review we illustrate the main molecular mechanisms linking obesity and cancer, focusing on the correlation between obesity and tumor risk, disease progression and response to chemo- and immunotherapy in patients with UC and the predictive/prognostic role of obesity in PCa patients treated with the currently available therapeutic approaches. Methods: We did a large-scale literature search on existing scientific websites focusing on keywords “obesity”, “body mass index (BMI)", “urothelial cancer”, “prostate cancer”, “docetaxel”, “cabazitaxel”, “abiraterone acetate”, “enzalutamide”, and “radium223". Results: Many adipocytes-induced molecules support tumor proliferation through activation of various cellular pathways. The available evidence in the postoperative setting do the role of BMI in oncological outcomes prediction still not completely clear. Likewise, in metastatic UC patients controversial results link the role of obesity/BMI with clinical outcomes of tumor response to chemotherapy. Adipose stromal cells recruitment, induced by PCa cells, from white adipose tissue to the tumor sites inducing cell invasiveness was associated with poor survival. Conflicting data, although more oriented towards a better survival outcome, resulted in obese patients treated with docetaxel. In PCa cell-lines a certain cabazitaxel chemo resistance adipose stromal cells (ASC)-mediated was demonstrated. In metastatic castration-resistant PCa patients with high BMI (>25 kg/m2) receiving abiraterone acetate there were significant worse survival outcomes, while in enzalutamide patients BMI did not affect survival outcome. In radium 223 patients higher BMI significantly correlated with favorable overall survival. Conclusions: The main focus of this review was to understand the interplay between obesity/BMI and UC/PCa. Several pathogenic cellular pathways exploring the issue are discussed, opening the way to challenging tailored treatments on the basis of BMI. Improving the knowledge of molecular connections between obesity and UC and PCa could favor the development of new therapies likely reducing chemo- and immunotherapy drug resistance.

Original languageEnglish (US)
Article number1225
JournalCancers
Volume11
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Prostatic Neoplasms
Obesity
Body Mass Index
Neoplasms
docetaxel
Survival
Stromal Cells
Drug Therapy
Immunotherapy
Radium
White Adipose Tissue
Castration
Drug Resistance
Adipocytes
Disease Progression
Therapeutics
Cell Line

Keywords

  • Adipose tissue
  • BMI
  • Obesity
  • Prostate cancer
  • Response to therapy
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Santoni, M., Cimadamore, A., Massari, F., Piva, F., Aurilio, G., Martignetti, A., ... Montironi, R. (2019). Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. Cancers, 11(9), [1225]. https://doi.org/10.3390/cancers11091225

Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. / Santoni, Matteo; Cimadamore, Alessia; Massari, Francesco; Piva, Francesco; Aurilio, Gaetano; Martignetti, Angelo; Scarpelli, Marina; Di Nunno, Vincenzo; Gatto, Lidia; Battelli, Nicola; Cheng, Liang; Lopez-Beltran, Antonio; Montironi, Rodolfo.

In: Cancers, Vol. 11, No. 9, 1225, 01.09.2019.

Research output: Contribution to journalArticle

Santoni, M, Cimadamore, A, Massari, F, Piva, F, Aurilio, G, Martignetti, A, Scarpelli, M, Di Nunno, V, Gatto, L, Battelli, N, Cheng, L, Lopez-Beltran, A & Montironi, R 2019, 'Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers', Cancers, vol. 11, no. 9, 1225. https://doi.org/10.3390/cancers11091225
Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A et al. Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. Cancers. 2019 Sep 1;11(9). 1225. https://doi.org/10.3390/cancers11091225
Santoni, Matteo ; Cimadamore, Alessia ; Massari, Francesco ; Piva, Francesco ; Aurilio, Gaetano ; Martignetti, Angelo ; Scarpelli, Marina ; Di Nunno, Vincenzo ; Gatto, Lidia ; Battelli, Nicola ; Cheng, Liang ; Lopez-Beltran, Antonio ; Montironi, Rodolfo. / Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. In: Cancers. 2019 ; Vol. 11, No. 9.
@article{5d848c444cde4d1f9f52837c2e3039b4,
title = "Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers",
abstract = "Background: In human populations, a certain amount of data correlate obesity/body mass index (BMI) with urothelial cancer (UC) and prostate cancer (PCa) occurrence, however this is not fully elucidated at all stages of disease. In an attempt to shed light on uncertain areas in such field, in the present review we illustrate the main molecular mechanisms linking obesity and cancer, focusing on the correlation between obesity and tumor risk, disease progression and response to chemo- and immunotherapy in patients with UC and the predictive/prognostic role of obesity in PCa patients treated with the currently available therapeutic approaches. Methods: We did a large-scale literature search on existing scientific websites focusing on keywords “obesity”, “body mass index (BMI){"}, “urothelial cancer”, “prostate cancer”, “docetaxel”, “cabazitaxel”, “abiraterone acetate”, “enzalutamide”, and “radium223{"}. Results: Many adipocytes-induced molecules support tumor proliferation through activation of various cellular pathways. The available evidence in the postoperative setting do the role of BMI in oncological outcomes prediction still not completely clear. Likewise, in metastatic UC patients controversial results link the role of obesity/BMI with clinical outcomes of tumor response to chemotherapy. Adipose stromal cells recruitment, induced by PCa cells, from white adipose tissue to the tumor sites inducing cell invasiveness was associated with poor survival. Conflicting data, although more oriented towards a better survival outcome, resulted in obese patients treated with docetaxel. In PCa cell-lines a certain cabazitaxel chemo resistance adipose stromal cells (ASC)-mediated was demonstrated. In metastatic castration-resistant PCa patients with high BMI (>25 kg/m2) receiving abiraterone acetate there were significant worse survival outcomes, while in enzalutamide patients BMI did not affect survival outcome. In radium 223 patients higher BMI significantly correlated with favorable overall survival. Conclusions: The main focus of this review was to understand the interplay between obesity/BMI and UC/PCa. Several pathogenic cellular pathways exploring the issue are discussed, opening the way to challenging tailored treatments on the basis of BMI. Improving the knowledge of molecular connections between obesity and UC and PCa could favor the development of new therapies likely reducing chemo- and immunotherapy drug resistance.",
keywords = "Adipose tissue, BMI, Obesity, Prostate cancer, Response to therapy, Urothelial cancer",
author = "Matteo Santoni and Alessia Cimadamore and Francesco Massari and Francesco Piva and Gaetano Aurilio and Angelo Martignetti and Marina Scarpelli and {Di Nunno}, Vincenzo and Lidia Gatto and Nicola Battelli and Liang Cheng and Antonio Lopez-Beltran and Rodolfo Montironi",
year = "2019",
month = "9",
day = "1",
doi = "10.3390/cancers11091225",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers

AU - Santoni, Matteo

AU - Cimadamore, Alessia

AU - Massari, Francesco

AU - Piva, Francesco

AU - Aurilio, Gaetano

AU - Martignetti, Angelo

AU - Scarpelli, Marina

AU - Di Nunno, Vincenzo

AU - Gatto, Lidia

AU - Battelli, Nicola

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: In human populations, a certain amount of data correlate obesity/body mass index (BMI) with urothelial cancer (UC) and prostate cancer (PCa) occurrence, however this is not fully elucidated at all stages of disease. In an attempt to shed light on uncertain areas in such field, in the present review we illustrate the main molecular mechanisms linking obesity and cancer, focusing on the correlation between obesity and tumor risk, disease progression and response to chemo- and immunotherapy in patients with UC and the predictive/prognostic role of obesity in PCa patients treated with the currently available therapeutic approaches. Methods: We did a large-scale literature search on existing scientific websites focusing on keywords “obesity”, “body mass index (BMI)", “urothelial cancer”, “prostate cancer”, “docetaxel”, “cabazitaxel”, “abiraterone acetate”, “enzalutamide”, and “radium223". Results: Many adipocytes-induced molecules support tumor proliferation through activation of various cellular pathways. The available evidence in the postoperative setting do the role of BMI in oncological outcomes prediction still not completely clear. Likewise, in metastatic UC patients controversial results link the role of obesity/BMI with clinical outcomes of tumor response to chemotherapy. Adipose stromal cells recruitment, induced by PCa cells, from white adipose tissue to the tumor sites inducing cell invasiveness was associated with poor survival. Conflicting data, although more oriented towards a better survival outcome, resulted in obese patients treated with docetaxel. In PCa cell-lines a certain cabazitaxel chemo resistance adipose stromal cells (ASC)-mediated was demonstrated. In metastatic castration-resistant PCa patients with high BMI (>25 kg/m2) receiving abiraterone acetate there were significant worse survival outcomes, while in enzalutamide patients BMI did not affect survival outcome. In radium 223 patients higher BMI significantly correlated with favorable overall survival. Conclusions: The main focus of this review was to understand the interplay between obesity/BMI and UC/PCa. Several pathogenic cellular pathways exploring the issue are discussed, opening the way to challenging tailored treatments on the basis of BMI. Improving the knowledge of molecular connections between obesity and UC and PCa could favor the development of new therapies likely reducing chemo- and immunotherapy drug resistance.

AB - Background: In human populations, a certain amount of data correlate obesity/body mass index (BMI) with urothelial cancer (UC) and prostate cancer (PCa) occurrence, however this is not fully elucidated at all stages of disease. In an attempt to shed light on uncertain areas in such field, in the present review we illustrate the main molecular mechanisms linking obesity and cancer, focusing on the correlation between obesity and tumor risk, disease progression and response to chemo- and immunotherapy in patients with UC and the predictive/prognostic role of obesity in PCa patients treated with the currently available therapeutic approaches. Methods: We did a large-scale literature search on existing scientific websites focusing on keywords “obesity”, “body mass index (BMI)", “urothelial cancer”, “prostate cancer”, “docetaxel”, “cabazitaxel”, “abiraterone acetate”, “enzalutamide”, and “radium223". Results: Many adipocytes-induced molecules support tumor proliferation through activation of various cellular pathways. The available evidence in the postoperative setting do the role of BMI in oncological outcomes prediction still not completely clear. Likewise, in metastatic UC patients controversial results link the role of obesity/BMI with clinical outcomes of tumor response to chemotherapy. Adipose stromal cells recruitment, induced by PCa cells, from white adipose tissue to the tumor sites inducing cell invasiveness was associated with poor survival. Conflicting data, although more oriented towards a better survival outcome, resulted in obese patients treated with docetaxel. In PCa cell-lines a certain cabazitaxel chemo resistance adipose stromal cells (ASC)-mediated was demonstrated. In metastatic castration-resistant PCa patients with high BMI (>25 kg/m2) receiving abiraterone acetate there were significant worse survival outcomes, while in enzalutamide patients BMI did not affect survival outcome. In radium 223 patients higher BMI significantly correlated with favorable overall survival. Conclusions: The main focus of this review was to understand the interplay between obesity/BMI and UC/PCa. Several pathogenic cellular pathways exploring the issue are discussed, opening the way to challenging tailored treatments on the basis of BMI. Improving the knowledge of molecular connections between obesity and UC and PCa could favor the development of new therapies likely reducing chemo- and immunotherapy drug resistance.

KW - Adipose tissue

KW - BMI

KW - Obesity

KW - Prostate cancer

KW - Response to therapy

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85071846656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071846656&partnerID=8YFLogxK

U2 - 10.3390/cancers11091225

DO - 10.3390/cancers11091225

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 9

M1 - 1225

ER -